BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gammon D, Cheng C, Volkovinskaia A, Baker GB, Dursun SM. Clozapine: Why Is It So Uniquely Effective in the Treatment of a Range of Neuropsychiatric Disorders? Biomolecules 2021;11:1030. [PMID: 34356654 DOI: 10.3390/biom11071030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Vasiliu O. Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence? Front Psychiatry 2022;13. [DOI: 10.3389/fpsyt.2022.1069432] [Reference Citation Analysis]
2 Ramai D, Mozell D, Facciorusso A, Kewalramani A, Chandan S, Dhindsa B, Dhaliwal A, Khan S, Adler DG. Medications and the risk of perforated appendicitis: an adverse event report system (FAERS) database analysis. Expert Review of Gastroenterology & Hepatology 2022. [DOI: 10.1080/17474124.2022.2143346] [Reference Citation Analysis]
3 Jiao S, Cao T, Cai H. Peripheral biomarkers of treatment-resistant schizophrenia: Genetic, inflammation and stress perspectives. Front Pharmacol 2022;13:1005702. [DOI: 10.3389/fphar.2022.1005702] [Reference Citation Analysis]
4 Lin C, Shih P, Emil Tsai G. Perspective Chapter: NMDA Treatments for CNS Disorders. Ketamine Revisited - New Insights into NMDA Inhibitors 2022. [DOI: 10.5772/intechopen.100528] [Reference Citation Analysis]
5 Barone A, De Prisco M, Altavilla B, Avagliano C, Balletta R, Buonaguro EF, Ciccarelli M, D'ambrosio L, Giordano S, Latte G, Matrone M, Milandri F, Francesco DN, Vellucci L, de Bartolomeis A. Disorganization domain as a putative predictor of Treatment Resistant Schizophrenia (TRS) diagnosis: A machine learning approach. Journal of Psychiatric Research 2022. [DOI: 10.1016/j.jpsychires.2022.09.044] [Reference Citation Analysis]
6 de Bartolomeis A, Vellucci L, Austin MC, De Simone G, Barone A. Rational and Translational Implications of D-Amino Acids for Treatment-Resistant Schizophrenia: From Neurobiology to the Clinics. Biomolecules 2022;12:909. [DOI: 10.3390/biom12070909] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Friedman JH, Hershkowitz D. Clozapine Use in a Movement Disorder Clinic. Clin Neuropharmacol 2022. [PMID: 35696620 DOI: 10.1097/WNF.0000000000000510] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Occhieppo VB, Basmadjian OM, Marchese NA, Jaime A, Pérez MF, Baiardi G, Bregonzio C. Schizophrenia-like endurable behavioral and neuroadaptive changes induced by ketamine administration involve Angiotensin II AT1receptor. Behav Brain Res 2022;:113809. [PMID: 35218792 DOI: 10.1016/j.bbr.2022.113809] [Reference Citation Analysis]
9 Raymond N, Lizano P, Kelly S, Hegde R, Keedy S, Pearlson GD, Gershon ES, Clementz BA, Tamminga CA, Keshavan M. What can clozapine’s effect on neural oscillations tell us about its therapeutic effects? A scoping review and synthesis. Biomarkers in Neuropsychiatry 2022. [DOI: 10.1016/j.bionps.2022.100048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]